Forbion — 2025 Investments
3 investments dated 2025 · listed companies and verified rows first · show all
BiotechRedwood City, US
Anatol Kreitzer(Executive Officer)Kristopher Hanson(Executive Officer)Erin Foff(Executive Officer)James Lillie(Executive Officer)Christopher A Kroeger(Executive Officer, Director)Jonathan Gillis(Executive Officer)
Board seatNanna Luneborg· per SEC Form D · $372.4M raise · filed Jul 2025
Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.
BiotechMedical DevicesBasel, CH
Patrick Loustau(President and Chief Executive Officer)
Co-investorsNovartis Venture FundSanofi VenturesVersant Ventures
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.
BiotechHealthtechMedical Devices
Ilise Lombardo(Chief Executive Officer)Volker Knappertz(Executive Vice President of Research & Development)Michael Samar(Chief Financial Officer)Rob Lasser(Chief Medical Officer)
Co-investorsBioMedPartnersJeito CapitalRoche Venture FundSofinnova PartnersEQTEQT Life Sciences+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.